Role of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash
|
|
- Ethan Parks
- 5 years ago
- Views:
Transcription
1 Review Article Vol. 24 No. 2 Nevirapine-associated rashes:- Manosuthi W & Sungkanuparph S. 89 Role of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash Weerawat Manosuthi, M.D.*, Somnuek Sungkanuparph, M.D.** ABSTRACT In the resource-limited countries, nevirapine (NVP)-based highly active antiretroviral therapy (HAART) has been widely used due to its availability and antiviral efficacy. Skin reaction is the most frequently observed adverse event from NVP. Both NVP and efavirenz (EFV) are in the same class of non-nucleoside reverse transcriptase inhibitor (NNRTI), and they also can cause skin rash and hypersensitivity reaction. To date, the previous clinical data may support the safety of subsequent use of efavirenz and encourage the physicians to use efavirenz in HIV-infected patients who had preceding nevirapine-associated skin rash. This review outlines the clinical safety data regarding use of EFV in HIV-infected patients who had preceding NVP-associated rash. (J Infect Dis Antimicrob Agents 2007;24:89-93.) INTRODUCTION Highly active antiretroviral therapy (HAART) has been widely used for the treatment of in patients with advanced HIV infection, and has been successful in achieving immune restoration and thus reducing morbidity and mortality. 1-3 Common initial HAART regimens consist of two nucleoside reverse transcriptase inhibitors (NRTIs), combined with either a boosted protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). The three currently available NNRTIs (nevirapine, efavirenz, and delavirdine) were introduced between 1996 and The choice between an NNRTI and a boosted PI remains largely a matter of opinion, but more clinical data favor NNRTI-based regimens. The current treatment guidelines for HIV-1- infected adults recommend the use of efavirenz in combination with zidovudine (ZDV) or tenofovir disoproxil fumarate (TDF) together with lamivudine (3TC) or emtricitabine (FTC) as one of the preferred first-line antiretroviral regimens. 4 However, the options of the initial HAART regimen should always be adapted to the individual situation with respect to compliance, concurrent opportunistic infections, concomitant *Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Tiwanon Road, Nonthaburi 11000, Thailand. **Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. Received for publication: October 2, Reprint request: Weerawat Manosuthi, M.D., Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Tiwanon Road, Nonthaburi 11000, Thailand. drweerawat@hotmail.com Keywords: HIV, efavirenz, nevirapine, rash 89
2 90 J INFECT DIS ANTIMICROB AGENTS May-Aug medications, accessibility, expense, and the needs of the patients. During the last few years, the first-line NNRTI-bases regimens have become increasingly popular, compared to PI-based regimens. NNRTIs are favored not only because of good clinical efficacy, but also because of lower pill burden, once-daily dosing with no restrictions regarding food intake, and avoidance of the perceived toxicity of PI-based regimens. All these factors contribute to better adherence to HAART, which is necessary for a sustained antiretroviral effect of treatment. 5 Nevertheless, a single mutation of NNRTI drug may lead to cross-class resistance. The NNRTIs that are currently available in Thailand are efavirenz and nevirapine. As mentioned earlier, efavirenz is the preferred NNRTI for an initial regimen. However, efavirenz is not a drug that is well tolerated by all patients, and the adverse reactions need to be carefully discussed to every patient before initiating this drug. Nevirapine is an NNRTI that has been shown to have high antiretroviral efficacy. 4-6 However, the 2006 US DHHS guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents still recommended two NRTIs plus nevirapine as an alternative regimen for the treatment of adults with HIV-1infection. 4 Nevirapine has been compared with efavirenz in the 2NN study, and was shown to be of comparable efficacy. 6 In resourcelimited countries, nevirapine-based HAART regimen has been widely used because it is more readily available and affordable than other regimens. In Thailand, the Government Pharmaceutical Organization (GPO) has produced a new formulation of antiretroviral drugs i.e., a fixed-dose combination of 30-mg or 40-mg stavudine (d4t), 150-mg 3TC, and 200-mg nevirapine (GPO-VIR S); and a fixed-dose combination of 250-mg ZDV, 150-mg 3TC, and 200-mg nevirapine (GPO-VIR Z) which have been available on the market since 2002 and 2006, 90 respectively. These generic combinations are components of the universal antiretroviral treatment coverage program in Thailand. Most of Thai HIVinfected patients can access to HAART. Regarding adverse reactions, skin rash is the most frequently observed adverse event associated with nevirapine, manifesting as diffuse maculopapular or erythematous rash with or without constitutional symptoms. The risk of rash of any severity is greatest within the first six weeks of treatment. 10 Generally, the rash is mild and transient. However, more severe rash including extensive maculopapular rash, serum sickness-like reaction, hypersensitivity syndrome, Steven-Johnson syndrome (SJS), and toxic epidermal necrolysis have been reported In addition, the severity of rash is not reduced by the co-administration of steroids, which should be avoided. Nevirapine shows autoinduction of cytochrome P450 isoenzymes, resulting in a decrease in the terminal half-life in plasma from 45 hours following a single dose to hours with multiple dosing. To account for this phenomenon, an initial reduced dose in the first two weeks of treatment before escalation to 400 mg/ day is recommended. The recommended dose of nevirapine 200 mg once daily for 14 days prior to escalation to 200 mg twice daily has been shown to reduce the frequency of rash. 4 Although this recommendation has been strictly followed, the overall frequency of rash ranges from 9 percent to 32 percent. 15 The incidence of nevirapine-associated skin reactions among Thai patients ranges from 6 percent to 21 percent. 7-9 The main adverse reaction, besides cutaneous manifestations, is hepatotoxicity. It usually occurs within the first month of nevirapine initiation. A recent data has shown a 12-fold higher incidence of serious hepatic events in women with CD4 cell counts of >250 cells/mm 3 and in men with CD4 cell counts of >400 cells/mm
3 Vol. 24 No. 2 Nevirapine-associated rashes:- Manosuthi W & Sungkanuparph S. 91 For the management of nevirapine-associated skin reactions, a mild skin reaction without mucous membrane involvement or development of transminase elevation can be treated with antihistamine. If this skin rash occurs during the first two weeks of initiation, the dose should not be increased until the rash has resolved completely. Nevirapine should be discontinued if severe rash occurrs as well as if other systemic symptoms occur such as fever, conjunctivitis, myalgia, arthralgia, and malaise. Due to nevirapine long half-life of approximately hours, the two NRTIs of the nevirapine-based HAART regimen should be continued after nevirapine discontinuation. It usually takes 7-14 days for nevirapine to be completely eliminated from the human body. A commonly known major disadvantage of the currently available NNRTIs is the low genetic barrier for the development of drug-resistant viral variants. Certain single amino-acid mutations in the NNRTIbinding region can cause a high level of drug resistance, such as K103N, Y181C, and Y188L. 12 Crossresistance between the currently licensed NNRTIs is extensive. A single mutation in the HIV-1 genome can increase the 50-percent inhibitory concentration (IC 50) by up to 100-fold. 12 The inter-patient variability of nevirapine clearance should be another concern This is attributable to the variation of half-life of this drug and may be difficult to predict individually. It s well established that a single-dose nevirapine is a highly cost-effective strategy to reduce perinatal HIV-1 transmission. However, its major disadvantage is the selection of nevirapine resistance in 20 percent to 30 percent of women. Muro and colleagues reported that most women who received a single 200-mg nevirapine dose still had detectable plasma concentrations of nevirapine after more than two weeks. 15 Thus, the purpose of tail-off management is to prevent occurrence of single amino-acid mutations that may limit the 91 efficacy of subsequent NNRTI drug. However, the future clinical study should be conducted to confirm the benefit of these techniques. Another concern is a that whether there is crosstoxicity between nevirapine and efavirenz in HIVinfected patients because both drugs belong to the NNRTI class and act similarly. Their molecular structure may not be related as nevirapine is a member of the dipyridodiazepinone class while efavirenz is a member of trifluoroderivate class. 16 In a resourcedlimited setting, patients can not afford the PI-based regimen due to its high cost. Thus, efavirenz-based HAART, which is more affordable, is an alternative regimen in HIV-infected patients with preceding nevirapine-associated skin rash. Although a hypersensitivity reaction can develop with both nevirapine and efavirenz, there have been no clinical data on the risk of cross-toxicity between these two drugs. We reviewed the literature from Medline database that reported the safety and tolerability of efavirenz in patients with preceding nevirapineassociated skin rash. However, there is a scarcity of clinical data in this area. Clarke and colleagues reported a small cohort of eight patients (four men and four women) with a mean CD4 cell count of 143 cells/mm A mean age was 45.7 years. Seven of eight patients had a history of antiretroviral treatment, with all seven having received multiple NRTIs and PIs. None of the patients had previously received an NNRTI. Six of the eight patients discontinued nevirapine due to skin rash of grade III, and the others due to liver toxicity. A mean duration of nevirapine treatment before a development of adverse reactions was 14.6 days. All patients had a washout period of seven to ten days before reinstitution of efavirenz-based HAART regimens. All eight patients in this cohort were successfully switched from nevirapine to efavirenz
4 92 J INFECT DIS ANTIMICROB AGENTS May-Aug treatment without recurrence of skin reactions. Soriano and colleagues reported seven of eight patients with nevirapine-associated skin rash could successfully switch from nevirapine to efavirenz treatment. 18 However, this report did not describe the details regarding a washout period before switching to efavirenz. In the study by Podzamczer and colleagurs, the authors described two HIV-infected patients who were able to tolerate efavirenz after having developed a severe hypersensitivity reaction due to nevirapine. 19 The latest study was conducted in Thai patients. 20 This retrospective cohort study was conducted in 122 HIV-infected patients diagnosed with nevirapineassociated rash and subsequently received efavirenz. All patients were followed-up for three months after receiving efavirenz. Possible risk factors were compared between those who had (group A) and did not have (group B) rash from efavirenz. Regarding preceding nevirapine-associated rash, 46 of the 122 (37.7%) patients had developed skin rash of level III. Of these 46 patients, 8 (6.6%) had developed nevirapine-associated Steven-Johnson syndrome. Of the122 patients, 10 (8.2%) developed rash from efavirenz and all needed efavirenz discontinuation. Baseline characteristics between group A (10 patients) and group B (112 patients) were similar. Median (IQR) time from nevirapine discontinuation to efavirenz initiation was 12 (9-21) days in group A and 11 (7-21) days in group B (p = 0.765). None of the possible risk factors investigated were associated with a subsequent development of efavirenz-associated skin rash. The overall incidence of efavirenz associated skin rash was 8.2 percent, and was relatively low when compared to a previous study conducted in Thai HIV-infected patients with higher CD4 cell counts who had no history of preceding nevirapine-associated skin rash. 7 The high incidence of NNRTI-related skin rash has been reported in females with high CD4 cell counts. 7,21 Although the 92 majority of skin reactions from efavirenz in this study was erythematous rash and was classified mild, the attending physicians decided to discontinue efavirenz. As described above, all of these data may support the safety of subsequent use of efavirenz and encourage the physicians to use efavirenz in HIV-infected patients with preceding nevirapine-associated skin rash. Efavirenz is more easily accessible than PIs in developing countries including Thailand. The application of a pharmacogenetic approach to antiretroviral drug therapy represents a significant challenge, such as drugdrug interactions and variability of drug metabolism within each individual. A better understanding of host genetic factors and adverse drug reactions would be helpful. To date, a pharmacogenomic study in this area is still lacking. The future clinical utility of pharmacogenomic testing in HIV management should be emphasized. In addition, a further study to determine immunologic and genetic factors associated with rash is needed. References 1. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosiscoinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43: Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: Health Services/Technology Assessment Text (HSTAT). Guidelines for the use of antiretroviral agents
5 Vol. 24 No. 2 Nevirapine-associated rashes:- Manosuthi W & Sungkanuparph S. 93 in HIV-infected adults and adolescents. Washington DC: Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation, May 4, Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34: van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised openlabel trial, the 2NN Study. Lancet 2004;363: Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005;19: Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004;87: Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006;43: Reisler K. High hepatotoxicity rate seen among HAART patients. AIDS Alert 2001;16: Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34 Suppl 1:S21-S Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside 93 inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39: Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005;10: Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006;42: Muro E, Droste JA, Hofstede HT, Bosch M, Dolmans W, Burger DM. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr 2005;39: Adkins JC, Noble S. Efavirenz. Drugs 1998;56: Clarke S, Harrington P, Barry M, Mulcahy F. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis 2000;31: Soriano V, Dona C, Barreiro P, Gonzalez-Lahoz J. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? AIDS 2000;14: Podzamczer D, Consiglio E, Ferrer E, Gudiol F. Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine. AIDS 2000;14: Manosuthi W, Thongyen S, Chumpathat N, Muangchana K, Sungkanuparph S. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash. HIV Med 2006;7: Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001;32:124-9.
Principles of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY Somnuek Sungkanuparph 1, Nopporn
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationChetchotisakd et al. Materials and Methods
High Rate Multiple Drug Resistances in HIV-Infected Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Thailand, Where Subtype A/E Is Predominant Ploenchan Chetchotisakd, MD, Siriluck
More informationCLINICALLY SIGNIFICANT DRUG INTERACTIONS AMONG HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
CLINICALLY SIGNIFICANT DRUG INTERACTIONS AMONG HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY Apichot So-Ngern 1, Preecha Montakantikul 2 and Weerawat Manosuthi 3 1 Faculty of Pharmacy, Siam University,
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationOpen Access , Thailand , Thailand. Bangkok 10400, Thailand. Keywords: HIV, model, nevirapine, prediction, rash, risk factor.
2 The Open AIDS Journal, 2009, 3, 2-30 Open Access A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-infected Patients: In Settings of Low CD Cell Counts and Resource Limitation
More informationRenal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
Original Article Vol. 29 No. 3 Renal safety of tenofovir:- Wiwattanathum P & Sungkanuparph S. 113 Renal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationEfficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children
International Journal of Infectious Diseases (2008) 12, e33 e38 http://intl.elsevierhealth.com/journals/ijid Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected
More informationThe prevalence of Stevens Johnson Syndrome caused by antiretroviral in hospitalized patients at Dr. Hasan Sadikin General Hospital Bandung
The prevalence of Stevens Johnson Syndrome caused by antiretroviral in hospitalized patients at Dr. Hasan Sadikin General Hospital Bandung Nurmilah Maelani*, Irna Sufiawati*, Hartati Purbo Darmadji** *Department
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationRecommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and
Recommendations for Use of Antiretroviral s in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, June 23, 2004, CDC and updated
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationThe Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients
American Journal of Infectious Diseases 4 (2): 147-151, 2008 ISSN 1553-6203 2008 Science Publications The Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationAssociation of Nevirapine Levels with Rash or Hepatotoxicity Among HIV- Infected Thai Women
Send Orders of Reprints at bspsaif@emirates.net.ae 266 The Open AIDS Journal, 2012, 6, 266-273 Open Access Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV- Infected Thai Women Winai
More informationDepartment of General Medicine, Juntendo University School of Medicine, Tokyo; and 2
Jpn. J. Infect. Dis., 69, 33 38, 2016 Original Article Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naäƒve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationNevirapine 200mg Tablet WHOPAR part 3 May 2005 Updated: May 2016 PACKAGE LEAFLET
PACKAGE LEAFLET PACKAGE LEAFLET Read this entire leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you have further questions, please ask your
More informationTreatment outcomes in HIV/tuberculosis co-infected patients with CD4 cell counts < 200 cells/mm 3 and 200 cells/mm 3
Original Article Vol. 29 No. 2 Treatment outcomes in HIV/TB co-infection:- Rattanamaneekorn S & Sungkanuparph S. 5 Treatment outcomes in HIV/tuberculosis co-infected patients with CD4 cell counts < 200
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationThe widespread use of antiretroviral therapy (ART) for the
ORIGINAL STUDIES Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor Based Antiretroviral Therapy Podjanee
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationReasons for Anti-Retroviral Regimen Changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia.
Reasons for Anti-Retroviral Regimen Changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia. LEMLEM GEBREMEDHIN *, AMANUEL BIRHANE 2, 2 Pharmacology and Toxicology course
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationWHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION. stavudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection
WHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION stavudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection 1. Summary statement of proposal for inclusion, change,
More informationEvidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation
Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016 - NHS England Evidence Review: Comparison of tenofovir alafenamide and tenofovir disoproxil fumarate.
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationnevirapine, zidovudine and lamivudine
nevirapine, zidovudine and lamivudine a fixed dose ART combination for HIV treatment http://www.aidsmap.com/hatip nevirapine. zidovudine and lamivudine (non-fixed dose) 2 Information on starting treatment
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationABACAVIR HYPERSENSITIVITY REACTION
ABACAVIR HYPERSENSITIVITY REACTION Key Risk Minimisation Points: Abacavir Hypersensitivity Reaction (HSR) Abacavir is associated with a risk for hypersensitivity reactions (HSR) characterised by fever
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationABACAVIR HYPERSENSITIVITY REACTION
ABACAVIR HYPERSENSITIVITY REACTION Abacavir is a component of Ziagen, Trizivir, Kivexa and Triumeq Triumeq is subject to additional monitoring UK/HIV/0042/15(3) October 2016 Slide Contents CONTENT SLIDES
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationPUBLIC HEALTH. HIV-infected patients HIV-infection toxicity adverse events virologic failure antiretroviral therapy. Key words:
e-issn 1643-3750 DOI: 10.12659/MSM.889283 Received: 2013.04.14 Accepted: 2013.05.14 Published: 2013.06.21 Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: A
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationBASELINE CD4 CELL COUNTS AND OUTCOMES AMONG ADULT TREATMENT NAÏVE HIV PATIENTS AFTER TAKING FIXED DOSE COMBINATION GPO-VIR-S AND GPO-VIR-Z IN THAILAND
Southeast Asian J Trop Med Public Health BASELINE CD4 CELL COUNTS AND OUTCOMES AMONG ADULT TREATMENT NAÏVE HIV PATIENTS AFTER TAKING FIXED DOSE COMBINATION GPO-VIR-S AND GPO-VIR-Z IN THAILAND Nyan Lin
More informationSURVEILLANCE OF HIV-1 DRUG-RESISTANCE MUTATIONS IN THAILAND FROM 1999 TO 2014
SURVEILLANCE OF HIV-1 DRUG-RESISTANCE MUTATIONS IN THAILAND FROM 1999 TO 2014 Nareenart Iemwimangsa 1, Ekawat Pasomsub 1, Chonlaphat Sukasem 2 and Wasun Chantratita 1 1 Division for Virology, 2 Division
More informationRenal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
Chua et al. AIDS Research and Therapy 2012, 9:19 SHORT REPORT Open Access Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Arlene C Chua 1*, Ryan M Llorin 1, Kelvin Lai
More informationDifference of opinion? Michelle Moorhouse 24 Sep 2014
Difference of opinion? Michelle Moorhouse 24 Sep 2014 Meet NN 52 years, female Nurse in pre-art clinic Referred Feb 2012 by dermatologist History of severe reactions to ART Erythema and bullous eruptions
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationLiver Toxicity in HIV Infected Patients Receiving Antiretroviral Therapy That Includes HIV I Protease Inhibitors.
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:2319-7676. Volume 11, Issue 4 Ver. IV (Jul. - Aug.2016), PP 99-103 www.iosrjournals.org Liver Toxicity in HIV Infected
More informationPharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV tuberculosis coinfection receiving rifampicin
Original article Antiviral Therapy 13:529 536 Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV tuberculosis coinfection receiving rifampicin Anchalee Avihingsanon
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 30 Dec 2018 00:34:16 GMT) CTRI Number CTRI/2009/091/000652 [Registered on: 27/10/2009] - Last Modified On 11/03/2014 Post Graduate Thesis Type of Trial
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationDespite the wealth of efficacy data from
OPTIMIZING HIV DRUG THERAPY * John G. Bartlett, MD ABSTRACT The clinical success of highly active antiretroviral therapy (HAART) in the treatment of human immunodeficiency virus disease is one of the great
More informationMechanisms of rifamycin-antiretroviral drug interactions
Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors Two previously published
More informationnevirapine, stavudine and lamivudine
nevirapine, stavudine and lamivudine Information on starting treatment with: nevirapine (NVP) + stavudine (d4t) + lamivudine (3TC) Nevirapine, stavudine and lamivudine (non-fixed dose) 2 Lead in dosing
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for REZOLSTA This is a summary of the risk management plan (RMP) for REZOLSTA. The RMP details important risks of REZOLSTA,
More informationClinical Management Guidelines 2012
Central American Course Monitoring and Evaluation for HIV/AIDS Policy and Program Management 1 2 3 4 Module 1 Unit 1 Clinical Management Guidelines 2012 National TB, HIV/AIDS & other STIs Programme Ministry
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationEFAVIRENZ ASSOCIATED STEVENS-JOHNSON SYNDROME
EFAVIRENZ ASSOCIATED STEVENS-JOHNSON SYNDROME To the Editor: Persons with human immunodeficiency virus (HIV) infection are highly susceptible to adverse dermatological reactions to specific medications
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationANTIRETROVIRAL THERAPY
ANTIRETROVIRAL THERAPY Editor s Note: Section III: Deciding When to Initiate ART is currently under revision due to recent data in favor of further expanding indications for antiretroviral therapy. What
More informationOutline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?
Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationA Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive Patients
Journal of US-China Medical Science 12 (2015) 85-89 doi: 10.17265/1548-6648/2015.02.008 D DAVID PUBLISHING A Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive
More informationDifferentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail
HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding
More informationThe Use of Resistance Testing in HIV
The Use of Resistance Testing in HIV Dushyantha Jayaweera, M.D., M.R.C.O.G., F.A.C.P. Professor in Clinical Medicine Division of Infectious Diseases University of Miami Miller School of Medicine Viral
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More information